Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8116 to 8130 of 8972 results

  1. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued Reference number: GID-TA11204

    Technology appraisal guidance
    Discontinued

  2. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Discontinued Reference number: GID-TA10869

    Technology appraisal guidance
    Discontinued

  3. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development Reference number: GID-TA10607 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued Reference number: GID-TA10126

    Technology appraisal guidance
    Discontinued

  5. Nintedanib for previously treated metastatic colorectal cancer [ID1030]

    Discontinued Reference number: GID-TA10138

    Technology appraisal guidance
    Discontinued

  6. Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

    Discontinued Reference number: GID-TA10140

    Technology appraisal guidance
    Discontinued

  7. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

    Discontinued Reference number: GID-TA10144

    Technology appraisal guidance
    Discontinued

  8. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued Reference number: GID-TA10148

    Technology appraisal guidance
    Discontinued

  9. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued Reference number: GID-TA10149

    Technology appraisal guidance
    Discontinued

  10. Peramivir for treating influenza [ID828]

    Discontinued Reference number: GID-TA10155

    Technology appraisal guidance
    Discontinued

  11. Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

    Discontinued Reference number: GID-TA10159

    Technology appraisal guidance
    Discontinued

  12. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued Reference number: GID-TA10180

    Technology appraisal guidance
    Discontinued

  13. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued Reference number: GID-TAG496

    Technology appraisal guidance
    Discontinued

  14. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

    Medical technologies guidance
    Discontinued

  15. Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503]

    Discontinued Reference number: GID-TA10401

    Technology appraisal guidance
    Discontinued